These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 20306655)

  • 41. Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.
    Dai D; Chen B; Tang H; Wang B; Zhao Z; Xie X; Wei W
    PLoS One; 2016; 11(8):e0161902. PubMed ID: 27561099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer?
    Pyke CM; Menezes G; Purdie DM; Johnson S; Cowley D
    Aust N Z J Surg; 1997 May; 67(5):256-9. PubMed ID: 9152154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
    Fujimoto Y; Higuchi T; Nishimukai A; Miyagawa Y; Kira A; Ozawa H; Bun A; Imamura M; Miyoshi Y
    J Surg Oncol; 2018 Jul; 118(1):228-237. PubMed ID: 29936704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer.
    Chen Z; Xu S; Su D; Liu W; Yang H; Xie S; Meng X; Lei L; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):486-94. PubMed ID: 25511546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
    Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
    Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating tumor DNA in Egyptian women with breast Cancer: A marker for detection of primary cases and early prediction of recurrence.
    Gameel AM; Talaat RM; Sakr MA; Selim MA; Abo Alil DFA; Elkhouly EA
    Clin Chim Acta; 2024 Aug; 562():119878. PubMed ID: 39047884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
    Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
    Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
    Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
    Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
    Krainer M; Brodowicz T; Zeillinger R; Wiltschke C; Scholten C; Seifert M; Kubista E; Zielinski CC
    Oncology; 1997; 54(6):475-81. PubMed ID: 9394844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients.
    Fan Y; Ren X; Liu X; Shi D; Xu E; Wang S; Liu Y
    Sci Rep; 2021 Mar; 11(1):6651. PubMed ID: 33758208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Ann Oncol; 2013 May; 24(5):1225-31. PubMed ID: 23230137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer].
    Chen Y; Zheng YH; Lin YY; Hu MH; Chen YS
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):842-6. PubMed ID: 22335950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
    Martín A; Corte MD; Alvarez AM; Rodriguez JC; Andicoechea A; Bongera M; Junquera S; Pidal D; Allende T; Muñiz JL; Vizoso F
    Anticancer Res; 2006; 26(5B):3965-71. PubMed ID: 17094428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
    Jiang XP; Yang DC; Elliott RL; Head JF
    Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.